Introduction: The Exosome Industry Formally Enters the "CMC Era"

As mesenchymal stromal/stem cell (MSC) therapies advance globally, regenerative medicine has found a new strategic focal point: the paracrine effect—the process by which cells secrete signals to communicate with their environment. Mounting scientific evidence indicates that the therapeutic benefits of MSCs in tissue repair, immunomodulation, and inflammation control do not depend entirely on the long-term engraftment and differentiation of the cells themselves. Instead, they derive primarily from a complex secretory network composed of extracellular vesicles (EVs), cytokines, lipid mediators, and functional nucleic acids (Phinney & Pittenger, 2017). Consequently, "cell-derived non-living cell products," represented by exosomes and the secretome, have rapidly emerged as the most active commercial frontiers in regenerative medicine.

However, industrial enthusiasm has long outpaced regulatory clarity. The exosome field has suffered from deep-seated issues, including terminological confusion, a lack of quality standards, limited scale-up capabilities, and ambiguous regulatory pathways. Particularly in Asian markets, numerous commercial products have flooded the medical aesthetics, consumer healthcare, and clinical grey markets without clear quality control systems, leaving the industry in a prolonged state of "high enthusiasm, low standards".

The official release of the Guidelines for Clinical Research Filing of Cell Components and Derivative Therapies (Version 1) in April 2026 marks a pivotal correction. China's regulatory framework has formally incorporated exosomes and related products into a regulatory framework that closely approximates that for biological drug products. The exosome industry has officially transitioned from a "concept competition phase" to a CMC (Chemistry, Manufacturing, and Controls)-driven era.

The core shift is profound: the Guidelines do not simply permit clinical research on exosomes. Instead, they explicitly mandate that these products must establish a complete formulation preparation and quality control system, a systematic non-clinical evaluation system, and scientifically rigorous clinical protocols aligned with biopharmaceutical development principles.

For process development teams and strategic decision-makers across the cell and gene therapy (CGT) sector, the competitive landscape has changed. The true core competency is no longer "whether you can extract exosomes", but rather "whether you can establish a stable, scalable, cost-effective industrial production platform with demonstrated batch-to-batch consistency."

1. Policy Background: From the "818 Regulations" to Unified Oversight

As a supporting technical framework under China's Regulations on the Administration of Clinical Research and Clinical Translation Application of Biomedical New Technologies (the "818 Regulations"), the Guidelines delineate clinical research on extracellular vesicles, the secretome, and organelle transfer, and address these areas beyond the traditional drug registration system. Instead, they govern them through a medical technology filing administration pathway.

This dual-track system divides clinical translation into two phases:

1. The Filing Phase: Research institutions conduct exploratory and confirmatory clinical studies following rigorous review by institutional academic and ethics committees.
2. The Clinical Translation Application Phase: Products undergo stringent technical approvals before routine application in medical institutions.

This framework preserves institutional space for early-stage exploration of frontier tech while enforcing standardised, tiered review.

The truly transformative shift, however, is the explicit requirement for a complete CMC system. Chapter 5 ("Formulation Preparation and Quality Control") mirrors traditional biopharmaceutical frameworks, encompassing:

• Source cell management and raw material control
• Process development and in-process control (IPC)
• Impurity profiling, analytical method validation, and stability studies
• Final release specifications

The regulatory logic has flipped from verifying the presence of exosomes to verifying that they can be produced industrially, reproducibly, and verifiably. This directly aligns with mainstream international consensus—such as the International Society for Extracellular Vesicles (ISEV) position paper (Witwer et al., 2019), which emphasises that EV therapies must establish quality systems akin to cell therapies.

By employing the broad term "cell components and derivatives", the Guidelines intentionally establish a unified framework that covers MSC-derived small EVs (exosomes and microvesicles), the cell secretome (conditioned medium concentrates), subcellular structures (mitochondria), and engineered/targeted vesicles. This adaptive vocabulary aligns with MISEV2023 standards (Welsh et al., 2024), preventing regulatory concepts from becoming obsolete as technology iterates, and carving out institutional space for future integration with RNA drugs, gene editing, and nanodelivery systems.

2. Process Research: Quality by Design & Upstream Industrial Logic

2.1 QbD Principles: Embedding Quality Within Process Design

The Guidelines state that preparation institutions should follow Quality by Design (QbD) principles, systematically introducing advanced international pharmaceutical concepts (such as ICH Q8(R2)) into cell derivatives. The essence of QbD is to embed quality attributes within process parameters during the design stage via risk assessments, rather than relying on passive end-product testing.

For complex biological products like EVs, Critical Quality Attributes (CQAs)—including particle size distribution, surface marker expression, cargo composition, and biological activity—are closely linked to cell sources, culture conditions, harvest timing, and downstream purification. Establishing a defined design space and utilising Process Analytical Technology (PAT) for real-time monitoring are now industrial imperatives.

2.2 The Two-Stage Culture Strategy

For process engineers, the Guidelines' explicit acknowledgement that "cell culture processes are generally divided into two stages: cell expansion culture and cell supernatant collection" is a major victory. This formally recognises the international gold standard for EV industrialisation: the two-stage culture strategy.

Historically, the EV industry has faced a fundamental contradiction: efficient MSC expansion typically relies on media containing serum or platelet lysate (PL), both of which are rich in exogenous particles, proteins, and foreign EVs Continuing with serum during the harvest phase introduces massive contamination (bovine EVs, platelet particles, serum aggregates), which severely compromises product purity and interferes with Nanoparticle Tracking Analysis (NTA) methods (Shelke et al., 2014).

The Guidelines explicitly support this two-stage model, stipulating that the collection medium must be serum-free, chemically defined, and meet strict sterility and endotoxin standards. Consequently, the harvest medium itself is now a critical, medical-grade raw material whose background particle profile directly impacts compliance.

2.3 Upstream Process Platforms: MSC Quality Dictates EV Quality

The Guidelines implicitly codify a vital scientific reality: EV quality fundamentally derives from MSC quality. EVs are essentially "molecular mirrors" that map the biological state of their source cells; their cargo composition is heavily influenced by oxygen concentration, inflammatory stimulation, culture density, metabolic state, and passage number (Phinney & Pittenger, 2017).

High-passage MSCs exhibit cellular senescence, DNA damage accumulation, and an expanded senescence-associated secretory phenotype (SASP), which systematically alters the miRNA and proteomic profiles of their secreted EVs, reducing efficacy and increasing risks. Thus, the passage number of MSCs must be treated as a Critical Process Parameter (CPP) linked directly to EV CQAs.

The industry is rapidly shifting toward 3D degradable microcarrier suspension culture combined with stirred-tank bioreactors (such as CytoNiche Biotech’s 3D TableTrix™, 3D RecomTrix™ microcarriers, and 3D FloTrix™ large-scale culture systems). This approach allows automated, closed GMP production and linear scale-up, ensuring cell uniformity while drastically increasing EV yield per batch.

2.4 Raw Material Control: Risk-Graded Management

The regulatory framework mandates a strict, risk-graded approach to raw materials. Animal-derived materials (e.g., bovine serum, Matrigel) pose significant immunogenicity and viral risks, requiring GMP-compliant preparation and rigorous pathogen screening. For human-derived materials, the screening requirements are exceptionally stringent, mandating testing for at least 16 distinct viral markers, including:

• Human EB virus and Human Cytomegalovirus (HCMV)
• Human retroviruses (HIV-1/2, HTLV-1/2)
• Hepatitis viruses (HAV, HBV, HCV)
• Parvovirus B19, HPV, Polyomavirus, Adenovirus, and Herpesviruses (6/7/8)

Furthermore, suppliers of commercial media must provide full ingredient lists and quality certificates. To navigate this compliance pressure, institutions must partner with upstream suppliers capable of executing comprehensive quality agreements and delivering stable, GMP-grade supplies that meet these 16 viral screening criteria natively (such as CytoNiche Biotech’s 3D FloTrix™ MSC serum-free medium, Model RMZ112).

2.5 Cell Bank Construction and Batch-to-Batch Consistency

The foundation of industrial consistency rests on a standardised, three-tier cell banking system: the Seed Cell Bank, the Master Cell Bank (MCB), and the Working Cell Bank (WCB). Passage stability studies must define the maximum scale and passage limits of each tier.

To demonstrate batch-to-batch consistency, developers must run consecutive representative production batches and cross-evaluate parameters, including particle size distribution, Zeta potential (reflecting colloidal stability and particle charge), surface marker expression, and functional activity. Any significant change in raw materials, production scale, or sites triggers mandatory multi-batch comparability studies to re-verify equivalence.

3. Quality Studies: The Multidimensional Quality Architecture

Chapter 5.5 establishes a multidimensional quality system that fully aligns with the ICH quality framework, focusing on identity, purity, impurities, integrity, stability, and biological potency.

Developers are required to characterise EVs using complementary analytical methods: Transmission Electron Microscopy (TEM) for morphology, Nanoparticle Tracking Analysis (NTA) for sizing, and Nano-flow Cytometry (NanoFCM) for phenotypic fingerprinting (verifying CD63/CD9/CD81 positivity while confirming the absence of cellular contaminants like calnexin or cytochrome C) (Théry et al., 2018; Webber & Clayton, 2013). The particle-to-protein ratio serves as a primary indicator of purity.

The true technical hurdle lies in the potency assay. Because extracellular vesicles function through complex, interwoven pathways—such as miRNA regulation, surface protein interactions, and cytoplasmic cargo delivery—a simple single-protein quantification is insufficient. Developing robust, cell-based matrix assays that directly correlate in vitro biological response with clinical efficacy will be the ultimate differentiator for successful medical-grade EV platforms.

Additionally, analytical method validation must comply with ICH Q2(R2) guidelines, and stability testing must follow ICH Q1 principles, where the deployment of specialised lyoprotectants (such as sucrose or trehalose) is critical to maintaining long-term vesicle membrane integrity and preventing cargo leakage during storage (Charoenviriyakul et al., 2018).

4. Non-clinical Research: Flexible, Evidence-Based Evaluation

4.1 A Science-Driven, Flexible Framework

The Guidelines reject a "one-size-fits-all" approach to non-clinical safety, mandating instead that evaluation depth match the specific characteristics and intended clinical use of the derivative technology. Crucially, non-clinical testing formulations must maintain strict fidelity to the intended clinical product—sharing identical cell sources, upstream processes, purification techniques, formulation compositions, and cryopreservation protocols to ensure that animal data has genuine predictive value for human safety.

Furthermore, chosen animal models must demonstrate biological responsiveness to human-derived EVs. Where species specificities present insurmountable barriers, advanced alternative platforms—such as humanised in vitro cell models, organoids, and microfluidic organ-on-a-chip technologies—should be utilised as complementary tools, directly embracing modern regulatory shifts toward the 3Rs principles (Replacement, Reduction, and Refinement).

4.2 Multidimensional Safety & Toxicity Assessment

General toxicology protocols must incorporate multiple dose and control groups to map clear dose-toxicity curves, alongside staggered necropsy time points to track acute versus delayed toxicities. If a product exhibits prolonged in vivo persistence, its biodistribution must be mapped, with special focus on cytokine release dynamics and potential tissue accumulation.

Immunological safety represents the most scrutinised domain within non-clinical testing. Because EVs carry highly active surface proteins and encapsulated nucleic acids, they can trigger unexpected immune pathways—such as cytokine storms, auto-immune cross-reactivity, or unintended immune tolerance—even while pursuing target immunomodulatory functions.

The Guidelines demand a dual evaluation of both cellular and humoral immunity indicators. For engineered vesicles carrying genetic modifications, the immunogenicity of the exogenous gene products is a priority testing item. If animal models are unreactive due to species barriers, developers must establish in vitro matrices, such as mixed lymphocyte reactions (MLR) and cytokine secretion profiling, to satisfy safety data requirements.

While native cell-derived components generally carry minimal genotoxic risks (and thus bypass standard genotoxicity matrices), engineered variants capable of genomic integration must undergo extensive genotoxicity assessments. Similarly, regarding tumorigenicity, the Guidelines pragmatically note that non-living cell derivatives:

"...generally do not present the direct tumorigenic risks associated with live cell transplantation."

However, they warn that enriching specific bioactive molecules can still disrupt the stability of recipient tissue cells. Systematic in vitro and in vivo oncogenic evaluations remain mandatory to secure a robust safety profile before human trials (Kalluri & LeBleu, 2020).

4.3 Efficacy and Metabolic Kinetics

In vivo efficacy must be confirmed in at least one relevant animal model prior to human trials, with clear biological effect biomarkers mapped to guide clinical dosing algorithms. For metabolic kinetics, the Guidelines openly acknowledge the methodological challenges of tracking native cell components due to their complex, endogenous compositions.

To resolve this, developers are directed to utilise multi-pronged tracking strategies (Görgens et al., 2022):

• Exogenous Labelling: Near-infrared fluorescent dye labelling coupled with small animal optical imaging.
• Endogenous Tracking: Quantitative PCR targeting donor-specific mitochondrial DNA sequences.
• Engineered Tracking: Quantitative PCR tracking specific transgene sequences in engineered variants.

5. Industry Strategic Implications: The Great Separation

From an industrial standpoint, the release of the Guidelines signals the commencement of the "industrialisation elimination round" for China’s exosome market. The speculative era of marketing "exosome concepts" is over; the baseline of enterprise valuation has completely transformed.

The questions defining the market leaders of tomorrow are stark:

• Do you possess large-scale, closed, automated production capacity?
• Is your industrialisation platform cost-effective at scale?
• Can you present statistically robust data for batch-to-batch consistency?
• Are your CQAs fully validated through methodologically sound analytical techniques (TEM, NTA, NanoFCM)?
• Do you have a validated release specification matrix and real-time stability data?

The winning entities will not be those selling standalone extraction kits or boutique lab-scale reagents. The future belongs to integrated, platform-based enterprises that control a comprehensive, end-to-end CMC workflow:

High-Density MSC Banks 

↓

Serum-Free Harvest Systems 

↓

Automated 3D Bioreactors

↓ 

Downstream Purification 

↓

Multidimensional QC Platforms 

↓

Lyophilised Final Formulations 

For clinical sponsors designing filing protocols under the 818 framework, the smartest strategic path is to proactively align quality matrices and data compilation with traditional Investigator-Initiated Trial (IIT) and New Drug Application (NDA) pathways. By ensuring early filing data complies with future pharmaceutical translation standards, developers can maximise the long-term value of their clinical investments.

The Guidelines are not an endpoint, but the primary launchpad for the clinical and commercial maturation of cell component and derivative therapies. In this new era, market dominance will not belong to those who merely claim the promise of exosomes, but to those who truly understand, measure, and systematically control them.

References

Charoenviriyakul, C., Takahashi, Y., Nishikawa, M., & Takakura, Y. (2018). Preservation of exosomes at room temperature using lyophilization. International Journal of Pharmaceutics, 553(1–2), 1–7. https://doi.org/10.1016/j.ijpharm.2018.10.032
Görgens, A., Bremer, M., Ferber, I., Floderer, M., McKelvey, K., Lopez, E., … El Andaloussi, S. (2022). Identification of storage conditions stabilizing clinical-grade extracellular vesicles preparations. Journal of Extracellular Vesicles, 11(6), e12238. https://doi.org/10.1002/jev2.12238
National Health Commission of the People's Republic of China. (April 2026). Guidelines for Clinical Research Filing of Cell Components and Derivative Therapies (Version 1). Official Website of the National Health Commission of the People's Republic of China.
International Council for Harmonisation. (2023). ICH Q2(R2): Validation of analytical procedures. https://www.ich.org/page/quality-guidelines
International Council for Harmonisation. (2023). ICH Q14: Analytical procedure development. https://www.ich.org/page/quality-guidelines
Kalluri, R., & LeBleu, V. S. (2020). The biology, function, and biomedical applications of exosomes. Science, 367(6478), eaau6977. https://doi.org/10.1126/science.aau6977
Na, T., Zhang, K., Zhao, L., Yao, X., Xu, C., Zhang, Y., Wang, L., Xu, M., Zhang, H., & Meng, S. (2026). Quality evaluation considerations for stem cell-derived extracellular vesicles-based therapeutic products in China. Journal of Extracellular Vesicles, 15, e70297. https://doi.org/10.1002/jev2.70297
Phinney, D. G., & Pittenger, M. F. (2017). Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells, 35(4), 851–858. https://doi.org/10.1002/stem.2575
Shelke, G. V., Lässer, C., Gho, Y. S., & Lötvall, J. (2014). Importance of exosome depletion protocols to eliminate functional and RNA-containing extracellular vesicles from fetal bovine serum. Journal of Extracellular Vesicles, 3(1), 24783. https://doi.org/10.3402/jev.v3.24783
Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., … Zuba-Surma, E. K. (2018). Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 7(1), 1535750. https://doi.org/10.1080/20013078.2018.1535750
Webber, J., & Clayton, A. (2013). How pure are your vesicles? Journal of Extracellular Vesicles, 2(1), 19861. https://doi.org/10.3402/jev.v2i0.19861
Welsh, J. A., Goberdhan, D. C. I., O'Driscoll, L., Buzas, E. I., Blenkiron, C., Bussolati, B., … Witwer, K. W. (2024). Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 13(2), e12404. https://doi.org/10.1002/jev2.12404
Witwer, K. W., Van Balkom, B. W. M., Bruno, S., Choo, A., Dominici, M., Gimona, M., … Giebel, B. (2019). Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. Journal of Extracellular Vesicles, 8(1), 1609206. https://doi.org/10.1080/20013078.2019.1609206